Company: NCEL
Filing Date: 2025-05-16
Form Type: 20-F
Source: 0001213900-25-044868
Chunk: 191

Company: NewcelX Ltd.
Filing Date: 2025-05-16
Form: 20-F
Item: Item 4
Chunk 191
---
 positive control drug. A preclinical study was conducted to observe the effects of NLS-12 on the memory in
the novel object recognition test in mice. The dose-ranging study using C57BL/6 male mice: 8 groups (N = 16 mice/group) were subjected
to the effect of NLS-12 (1, 4, 8 mg/kg) and compared to those of vehicle and of donepezil (2 mg/kg). Long-term episodic memory was tested
in the NOR test, using a 3-days interval between the acquisition session (called sample trial) and the retention session (called choice
trial). NLS-12 dose-dependently improved the recognition of the familiar object, i. e. improved memory. This effect was significant at
8 mg/kg and was not significantly different to that of donepezil. The recognition of the familiar object was not modified by NLS-12 (1
mg/kg) and was improved in a non-significant manner by NLS-12 (4 mg/kg). The results of this pre-clinical study suggest that NLS-12 induced
a long-term memory improvement which was significant and of the same extent to that induced by donepezil.

Aexon CNS Platform

Aexon conducts research on
new compounds to address unmet needs in neurodegenerative disorders, defined by the breakdown of neurons over time. Alzheimer’s,
Parkinson’s, Huntington’s, Narcolepsy and Amyotrophic Lateral Sclerosis are just a few examples of brain disorders that have
no cure. Eric Konofal, MD, PhD, who works under a part-time consulting agreement for us as our Chief Scientific Officer, is the president
and founder of Aexon, and owns 59% of Aexon. Alexander Zwyer, our Chief Executive Officer, owns 35% of Aexon. Mr. Zwyer holds no board
or executive position at Aexon.

On March 20, 2024, we
announced that we entered into an exclusive worldwide license agreement with Aexon, a privately held Delaware corporation, under
which we acquired full global development and commercialization rights to Aexon’s Dual Orexin Receptor Agonists platform, new
molecular entities, highly selective dual oral orexin-1 and orexin-2 receptor agonists (OX1R and OX2R) with potential applications
in the treatment of narcolepsy and idiopathic hypers